Hepatitis A vaccination coverage amongst people with Chronic Liver Disease in England (HEALD): protocol for a retrospective cohort study

Hepatitis A vaccination coverage amongst people with Chronic Liver Disease in England (HEALD): protocol for a retrospective cohort sentinel network database study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN11919759

Enrollment

1650

Registered

2023-10-12

Start date

2023-06-06

Completion date

Unknown

Last updated

2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

People with chronic liver disease, including alcohol-related liver disease (ALD), chronic hepatitis B infection (CH-B), chronic hepatitis C infection (CH-C), and non-alcoholic fatty liver disease (NAFLD) Digestive System

Interventions

Using data from the Primary Care Sentinel Cohort (PCSC) of the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance centre (RSC) for the period between the 1st January 2012 a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: We will include adults registered in general practices within the RSC network, with a diagnosis of CLD, as defined by our ontology, within the period between the 1st January 2012 and 31st December 2022. The following inclusion criteria will be applied: People registered in the RSC general practices, aged 18 years of age and older, with a diagnosis of CLD. Our ontology for CLD includes: Alcoholic liver disease (ALD), chronic hepatitis B (CH-B), chronic hepatitis C (CH-C), non-alcoholic fatty liver disease, Wilson´s Disease, haemochromatosis, autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).

Exclusion criteria

Exclusion criteria: 1. Patients with recorded contraindications to the Hep A vaccine (confirmed anaphylactic reaction to a previous dose of Hep A containing vaccine, or to any of its components). 2. Records of administration of post-infection or risk-of-infection immunoglobulins.

Design outcomes

Primary

Measure	Time frame
Number of doses of hepatitis A vaccination measured using patient records at a single time point	—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

England, United Kingdom, Wales

Contacts

Public ContactBernardo Meza

bernardo.meza-torres@phc.ox.ac.uk+44 1865 617855

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026